CI
RVMD icon

CX Institutional’s Revolution Medicines RVMD Stock Holding History

CX Institutional’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25K Buy
132
+27
+26% +$3.94K ﹤0.01% 1125
2026
Q1 		$10K Buy
+105
New +$10.6K ﹤0.01% 1304

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

CX Institutional's RVMD Position: Q2 2026 in Review

CX Institutional increased its Revolution Medicines (RVMD) stake by 26% in Q2 2026, buying an estimated $3.94K and bringing the position to 132 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #1125.

CX Institutional first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • CX Institutional held 132 shares of Revolution Medicines worth $25K as of Q2 2026.
  • CX Institutional bought 27 Revolution Medicines shares in Q2 2026, an estimated $3.94K.
  • Revolution Medicines made up ﹤0.01% of CX Institutional's portfolio in Q2 2026, its #1125 holding.
  • CX Institutional first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.